Linked Life Data

16324867

Source:http://linkedlifedata.com/resource/pubmed/id/16324867

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1-2
pubmed:dateCreated
2006-3-27
pubmed:abstractText
Chemotherapy of sarcomas includes two major drugs: doxorubicin, ifosfamide and a third, dacarbazine, whose effectiveness remains marginal. The current challenge consists in improving the combination of these drugs, in particular by modulating their amounts. New molecules of chemotherapy show their efficiency in sarcomas. Among those, one will note above all gemcitabine and ET-743, in some sub-types. Target therapies and antiangiogenic treatment have also begun to show results. It is advisable from now on to distinguish the different sub-type of sarcomas in order to assess cytotoxic activity.
pubmed:language
fre
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1278-3218
pubmed:author
pubmed:issnType
Print
pubmed:volume
10
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
72-7
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:articleTitle
[Chemotherapy of sarcomas: optimization of existing drugs and new molecules].
pubmed:affiliation
Service d'Oncologie Médicale, pavillon E, Hôpital Edouard-Herriot, Lyon, France. jfayette@free.fr
pubmed:publicationType
Journal Article, English Abstract, Review